Search results
Results from the WOW.Com Content Network
The U.S. Food and Drug Administration's (FDA) panel voted 12 to 1 against the late-stage data submitted by Merck for the drug gefapixant, which showed a small reduction in cough frequency compared ...
The FDA's decision gives some breathing room to rival GSK's chronic cough treatment camlipixant, which is in late-stage development with anticipated regulatory approval and launch in 2026 ...
The panel will deliberate whether the data provided by Merck establishes that a small reduction in cough frequency with the use of gefapixant is clinically meaningful to patients. US FDA staff ...
Camlipixant is an investigational new drug that is being evaluated for the treatment of chronic cough. [1] It is a P2X3 receptor antagonist. [2] See also. gefapixant;
Gefapixant, sold under the brand name Lyfnua, is a medication used to treat chronic (long-term) cough. [1] It acts as an antagonist of the P2RX3 receptor. [2] [3] [4]
Guaifenesin/codeine is a fixed-dose combination cold medicine used for the treatment of cough. [1] It contains guaifenesin, an expectorant; and codeine, as the phosphate, an opioid antitussive. [1]
Benzonatate is a prescription non-opioid alternative for the symptomatic relief of cough.[7] [9] It has been found to improve cough associated with a variety of respiratory conditions including asthma, bronchitis, pneumonia, tuberculosis, pneumothorax, opioid-resistant cough in lung cancer, and emphysema.
An adenosine receptor antagonist is a drug which acts as an antagonist of one or more of the adenosine receptors. [1] The best known are xanthines and their derivatives (natural: caffeine, [2] theophylline, [3] and theobromine; and synthetic: PSB-1901 [4]), but there are also non-xanthine representatives (e.g. ISAM-140, [5] ISAM-R316, [6] etrumadenant, [7] and AZD-4635 [8])